Compare RUM & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RUM | STOK |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | 135 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | N/A | 2019 |
| Metric | RUM | STOK |
|---|---|---|
| Price | $4.98 | $32.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $10.00 | ★ $39.20 |
| AVG Volume (30 Days) | ★ 1.8M | 807.3K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.73 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $184,420,000.00 |
| Revenue This Year | $209.98 | N/A |
| Revenue Next Year | $40.99 | $82.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 404.50 |
| 52 Week Low | $4.62 | $5.35 |
| 52 Week High | $10.99 | $40.22 |
| Indicator | RUM | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 42.74 | 47.41 |
| Support Level | $4.67 | $32.70 |
| Resistance Level | $7.02 | $35.63 |
| Average True Range (ATR) | 0.23 | 2.38 |
| MACD | -0.00 | -0.23 |
| Stochastic Oscillator | 40.47 | 53.03 |
Rumble Inc is a free-to-use video-sharing platform where users can watch, share, like, comment, and upload their own videos. Users can subscribe to channels to stay in touch with recent creator content and access video-on-demand uploaded, and live content streamed, by creators. Geographically, it generates a majority of its revenue from the United States.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.